Understanding the natural history of KSHV-associated Multicentric Castleman Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the natural history and biology of KSHV-associated Multicentric Castleman Disease (MCD), a rare and severe condition often seen in HIV-infected individuals. By examining the disease's progression and the effectiveness of existing treatments, the study seeks to enhance understanding of how KSHV-MCD affects patients and to identify potential new therapeutic strategies. The research will involve patients with biopsy-proven KSHV-MCD and will assess their health outcomes over time. The findings may contribute to improved treatment protocols for this challenging condition.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Biopsy proven KSHV-associated MCD, confirmed in the Laboratory of Pathology (LP), CCR
* Age \>=18 years.
* ECOG performance status \<=4 (Karnofsky \>=20%).
* Ability of subject to understand and the willingness to sign a written informed consent document.
* Participants may be co-enrolled in other protocols, including investigational studies to treat KSHV-associated malignancies.

EXCLUSION CRITERIA:

* Any condition or set of circumstances that in the opinion of the investigators would make participation in this study unsafe or otherwise inappropriate for a given individual.
* Pregnancy

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Ramya M Ramaswami, M.D. — National Cancer Institute (NCI)
• Study coordinator: Irene B Ekwede, R.N.
• Email: irene.ekwede@nih.gov
• Phone: (240) 760-6126

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Collecting samples from patients with HIV and related conditions

  This study is collecting blood and tissue samples from adults with HIV and related cancers to help researchers learn more about these conditions.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00006518

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• Testing pacritinib for treating KSHV-related diseases

  This study is testing if the drug pacritinib can help people with KSHV-related diseases like Kaposi sarcoma and multicentric Castleman disease feel better and reduce inflammation.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06052618

• New treatment approach for idiopathic multicentric Castleman disease using an anti-IL-6 receptor antibody

  This Phase 3 study tests whether the anti-IL-6 receptor antibody VDJ001 can help adults with idiopathic multicentric Castleman disease.

  Recruiting Phase 3 Beijing VDJBio Co., LTD. · Beijing, Beijing Municipality and 7 other locations · NCT07872423

• Collecting blood and tissue samples for HIV/AIDS-related cancer research

  This study is collecting blood and tissue samples from people living with HIV and related cancers to help researchers learn more about how HIV affects cancer development.

  Recruiting at 8 sites AIDS Malignancy Consortium · La Jolla, California and 7 other locations · NCT05663502

• Ruxolitinib for adults with previously treated idiopathic multicentric Castleman disease

  This trial will try ruxolitinib (Jakafi) in adults with iMCD who did not improve with or cannot take siltuximab or tocilizumab.

  Recruiting Phase 2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07085039

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.